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Objective: The present study evaluated the prognostic signiﬁcance of apoptosis-related pro-
teins p53, Bax and galectin-3 in patients with non-small cell lung cancer (NSCLC) treated
with surgical resection.
Methods: We investigated the expression of these proteins and their association with clinico-
pathologic characteristics including disease-free survival (DFS) and overall survival (OS) in
205 NSCLC patients who underwent surgical resection (Stage I, 97; II, 46; IIIA, 45; IIIB, 17)
using immunohistochemistry. Eighty-eight patients (43%) received adjuvant treatment
(chemotherapy: 8, radiotherapy: 24, both: 56).
Results: High expressions of Bax, p53 and galectin-3 were observed in 48 (23%), 81 (40%)
and 105 (51%) patients, respectively. Low expression of Bax was signiﬁcantly associated with
male gender, squamous cell histology and low expression of galectin-3. Five-year DFS and
OS of total patients were 37 and 46%, respectively. High expressions of p53 and galectin-3
were not associated with poor DFS or OS, and no signiﬁcant correlation existed between low
expression of Bax and outcome of patients. However, in patients with non-squamous his-
tology (108 patients), low expression of Bax was a signiﬁcant independent predictor of poor
DFS (P ¼ 0.017) and OS (P ¼ 0.037). In addition, in patients with Stage II or III disease, low
expression of Bax signiﬁcantly correlated with poor DFS (P ¼ 0.004). It was also the most sig-
niﬁcant independent poor prognostic factor second only to a large primary tumor size in
Stage II or III patients with non-squamous histology.
Conclusions: Low expression of Bax was signiﬁcantly associated with poor prognosis in
resected NSCLC patients with non-squamous histology.
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INTRODUCTION
Lung cancer is the most common malignancy in many
countries and it has become the number one cause of cancer
death in Korea, surpassing gastric cancer (1,2). Majority
of lung cancer patients has non-small cell type, in which sur-
gical resection is still the mainstay of the curative treatment
(2). However, the prognosis of patients with non-small cell
lung cancer (NSCLC) is still poor despite surgical treatment
(2,3). Recently, several phase III trials demonstrated
improved survival with adjuvant chemotherapy, especially in
patients with Stage II or III disease (4–7). Therefore, the
determination of parameters that may identify those patients
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who would not, has strong clinical implications.
Apoptosis-related proteins are important candidates for such
parameters, because apoptosis is the predominant mechanism
in which chemotherapy and radiotherapy kill the cancer cells
(8). Among several proteins involved in apoptosis, the ﬁne
interplay between the anti-apoptotic members of the Bcl-2
family and the death-promoting members such as Bax and
p53 has been suggested as the most important process (8).
BH3-only proteins or p53 directly or indirectly activate the
Bax protein, which permeabilizes the mitochondrial outer
membrane, leading to the activation of downstream apoptosis
signaling pathways (8,9). In addition, galectin-3, which
belongs to a family of the galactoside-binding protein-3, and
is structurally and functionally similar to Bcl-2, is known to
protect cells from apoptosis by various stimuli (10).
Therefore, genetic defects in these proteins may not only
result in intrinsic biologic aggressiveness, but also lead to
resistance to the cytotoxic effects of chemotherapy and
radiotherapy (8,11–13). We evaluated the prognostic signiﬁ-
cance of apoptosis-related proteins p53, Bax and galectin-3
in NSCLC patients treated with surgical resection with or
without adjuvant treatment.
PATIENTS AND METHODS
PATIENTS
Two hundred and ﬁve patients who underwent resection of
primary NSCLC at Ajou University Medical Center between
September 1996 and December 2002 were eligible to be
included in this retrospective study. Patients with a history
of cancer from a non-pulmonary origin were included if
the disease was cured. Exclusion criteria included patients
with history of previous lung cancer, a Stage IV disease and
those treated preoperatively with either chemotherapy or
radiotherapy. Before operation, each patient underwent the
following staging procedures: chest radiography, chest
computed tomography (CT) scan and hematologic and bio-
chemical proﬁles. The American Joint Committee on Cancer
staging was used for post-operative pathologic staging of the
patients (14). This research protocol was approved by the
Institutional Review Board of the Ajou University Medical
Center, Suwon, Korea.
CHEMOTHERAPY
In the majority of patients in Stage II or III, adjuvant
chemotherapy was performed according to the discretion of
physicians. Although adjuvant chemotherapy regimens were
not uniformly applied, all, except three, patients received
cisplatin-based chemotherapy (gemcitabine, tegracil and
gemcitabine/carboplatin, respectively). The most commonly
administered regimen (24 patients) consisted of two cycles
of etoposide/cisplatin chemotherapy followed by concurrent
chemoradiotherapy with cisplatin. In this regimen, etoposide
100 mg/m
2/day (Days 1–3) and cisplatin 20 mg/m
2/day
(Days 1–4) were administered every 3 weeks, while con-
current chemoradiotherapy consisted of radiotherapy with
Figure 1. Immunohistochemical staining of apoptosis-related proteins in non-small cell lung cancer (400). (A) High expression of Bax: cytoplasmic staining
(Grade 3 in the intensity). (B) Low expression of Bax (Grade 1 in the intensity). (C) High expression of p53: nuclear staining (Grade 3 in the extent). (D)
High expression of galectin-3: cytoplasmic staining (Grade 3 in the intensity).
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2/day for 4 days during Weeks 1 and 4 of
radiotherapy.
RADIOTHERAPY
Radiotherapy was performed using 6- or 15-MV LINAC
(CLINAC 2100CD, Varian Medical Systems, Palo Alto, CA,
USA). Patients were treated with multiple portals, and a con-
formal isodose plan was created. The target volume was the
bronchial stump, and ipsilateral hilar and mediastinal lymph
nodes with a 1–2 cm margin. The primary tumor bed was
included when there was chest wall invasion. The radiation
dose to target volume was 50.4 Gy in 27–30 fractions,
5 days/week when corrections for inhomogeneity were not
made. After inhomogeneity corrections were made, radiation
of 54–60 Gy in 27–30 fractions were delivered to the target
volume. Boost radiation of 10–15 Gy was required when the
tumor cells were on the resection margins. The dose to the
spinal cord did not exceed 45 Gy.
EVALUATION
The patients were followed with chest radiography either
with or without chest CT scan every 3 months for 2 years,
then every 6 months for 3 years and yearly thereafter.
CONSTRUCTION OF TISSUE MICROARRAY AND
IMMUNOHISTOCHEMICAL STAINING FOR APOPTOSIS-RELATED
PROTEINS
Two representative areas were taken of all cases from
parafﬁn tissue blocks after reviewing the hematoxylin–
eosin-stained slides of the primary tumor. A total of 410
core tissue biopsies (diameter, 1.0 mm) were taken and
arrayed into three new recipient parafﬁn blocks.
Five-micrometer sections of these tissue array blocks were
then cut, placed on charged poly-L-lysine–coated slides and
used for immunohistochemical analysis.
Sections from the tissue array were deparafﬁnized in
xylene and were rehydrated in graded alcohol and water.
Endogenous peroxidase activity was blocked by treatment
with 3% hydrogen peroxide for 10 min. Sections were
treated with a protein-blocking solution and then with
primary antibodies, including mouse anti-human monoclonal
antibodies against p53 (DO-7, dilution 1:20) and galectin-3
(NCL-GAL3, dilution 1:100) (Novocastra Laboratories Ltd,
Newcastle upon Tyne, UK), and rabbit anti-human poly-
clonal antibody against Bax (dilution 1:1000, DAKO,
Carpinteria, CA, USA), for 1 h at room temperature. After
rinsing several times in phosphate-buffered saline, the sec-
tions were incubated in biotinylated secondary antibody.
Bound antibodies were detected by the streptavidin–biotin
method with a Cap-Plus detection kit (Zymed Laboratories
Table 1. Expression of Bax and clinicopathologic characteristics
Low
Bax (%)
High
Bax (%)
P value
a
Gender
Female 22 (14) 23 (48) ,0.0001
Male 135 (86) 25 (52)
Age
63
b 84 (54) 28 (58) 0.621
.63 73 (46) 20 (42)
History of smoking
Yes 140 (89) 25 (52) ,0.0001
No 17 (11) 23 (48)
Operation
Lobectomy
c 100 (64) 39 (81) 0.023
Pneumonectomy 57 (36) 9 (19)
Histologic types
Squamous 89 (57) 7 (15) ,0.0001
Adeno 54 (34) 36 (75)
Adenosquamous 7 (4) 5 (10)
Others
d 7 (4) 0 (0)
Tumor size (cm)
3.9
e 76 (48) 29 (60) 0.187
.3.9 81 (52) 19 (40)
Stage
f
I 72 (46) 25 (52) 0.658
II 38 (24) 8 (17)
IIIA 35 (22) 10 (21)
IIIB 12 (8) 5 (10)
Resection margin
Negative 140 (89) 45 (94) 0.420
Positive 17 (11) 3 (6)
Adjuvant treatment
No 89 (57) 28 (58) 0.773
Chemotherapy 7 (4) 1 (2)
Chemoradiotherapy 44 (28) 12 (25)
Radiotherapy 17 (11) 7 (15)
Expression of p53
Low 89 (57) 35 (73) 0.063
High 68 (43) 13 (27)
Expression of galectin-3
Low 88 (56) 12 (25) ,0.0001
High 69 (44) 36 (75)
aFisher’s exact test.
bMedian age.
cIncluding two patients with wedge
resection.
dIncluding ﬁve patients with large cell carcinoma, one with
mucoepidermoid carcinoma and one with carcinosarcoma.
eMedian longest
diameter of primary tumor.
fPost-operative pathologic staging.
Jpn J Clin Oncol 2008;38(10) 663Inc, San Francisco, CA, USA). Slides were rinsed in
phosphate-buffered saline, exposed to diaminobenzidine and
counterstained with Mayer’s hematoxylin. The negative con-
trols for these proteins were made by omitting the primary
antibody during the process of immunohistochemical stain-
ing. For positive controls of p53 and Bax, a tissue section of
colon adenocarcinoma known to have high expression of
p53 and lymphocytes in the germinal center were used,
respectively, while a tissue section of the tonsil was used as
the positive control for galectin-3.
The slides were examined independently by two observers
(JHH, JHK) blinded to both clinical and pathologic data.
Expression of the apoptosis-related proteins was quantiﬁed
using a visual grading system based on the extent of staining
(percentage of positive tumor cells) (graded on a scale of
0–3; 0, 0–25%; 1, 26–50%; 2, 51–75%; 3, .75%) for
p53, and the intensity of staining (graded on a scale of 0–3;
0, no staining; 1, weak staining; 2, moderate staining; 3,
strong staining) for Bax and galectin-3, respectively. There
was close agreement (.90%) in the evaluation of apoptosis-
related proteins between both investigators. In case of dis-
agreement, ﬁnal grading was determined by consensus.
Expression of apoptosis-related proteins was classiﬁed into
high (Grade 2, 3) and low (Grade 0, 1) expressions (Fig. 1).
STATISTICAL ANALYSIS
Disease-free survival (DFS) and overall survival (OS) were
calculated using the Kaplan–Meier method (15). DFS was
deﬁned as the time from the day of operation to a documen-
ted day of recurrence, development of a second primary
cancer or death from any other cause. Data on patients who
did not experience recurrence were censored at the last
follow-up. OS was deﬁned as the time from the day of oper-
ation to the time of death; data on survivors were censored at
the last follow-up. The differences between the survival
curves were tested using the log-rank test and the Wilcoxon
test. The Cox proportional-hazards regression model was
used to determine the joint effects of several variables on
survival (16). The comparison of clinicopathologic charac-
teristics was evaluated with the Fisher’s exact test. All stat-
istical analyses were performed two-sided, with SPSS for
Windows 12.0 software.
RESULTS
PATIENT CHARACTERISTICS
The median age of 205 patients with NSCLC was 63 years
(range: 30–78), and the median longest diameter of the
primary tumor was 3.9 cm (1.2–12). Twenty-six patients
(13%) were in Stage IA, 71 (35%) in IB, 7 (3%) in IIA, 39
(19%) in IIB, 45 (22%) in IIIA and 17 (8%) in IIIB. One
hundred and ﬁfty-eight male patients (99%) and seven
female patients (16%) had a history of smoking (current or
previous smoker). In terms of histologic type, 98% of
patients with squamous cell carcinoma had a history
of smoking, while 63% of adenocarcinoma patients and 74%
of patients with other histologic types were current or pre-
vious smokers. Other clinicopathologic characteristics of the
patients are listed in Table 1.
ASSOCIATION OF EXPRESSION OF APOPTOSIS-RELATED PROTEINS
WITH CLINICOPATHOLOGIC CHARACTERISTICS
High expressions of Bax, p53 and galectin-3 were observed in
48 (23%), 81 (40%) and 105 (51%) patients, respectively.
High expression of p53 was associated with male gender (P ¼
Table 2. Relationship between the expression of apoptosis-related proteins and subtypes of adenocarcinoma
Subtype Bax p53 Galectin-3
Low (%) High (%) P value
a Low (%) High (%) P value
a Low (%) High (%) P value
a
Acinar 38 (70) 22 (61) 0.094 42 (67) 18 (67) 0.093 21 (78) 39 (62) 0.622
BAC 6 (11) 10 (28) 12 (19) 4 (15) 3 (11) 13 (21)
Papillary 3 (6) 3 (8) 6 (10) 0 (0) 1 (4) 5 (8)
Solid
b 7 (13) 1 (3) 3 (5) 5 (19) 2 (7) 6 (10)
BAC, Bronchioloalveolar carcinoma.
aFisher’s exact test.
bIncluding one patient with signet-ring adenocarcinoma.
Figure 2. Disease-free and overall survival of resected non-small cell lung
cancer patients.
664 Low expression of Bax in non-small cell lung cancer0.024), history of smoking (P ¼ 0.002), post-pneumonectomy
status (P ¼ 0.046) and squamous cell histology (P ¼ 0.033).
In addition, high expression of galectin-3 correlated with
no smoking history (P ¼ 0.023), post-lobectomy status
(P ¼ 0.011), adenocarcinoma (P , 0.0001) and negative
resection margin (P ¼ 0.018). Low expression of Bax was sig-
niﬁcantly associated with male gender (P , 0.0001), history
of smoking (P , 0.0001), squamous cell histology (P ,
0.0001) and low expression of galectin-3 (P , 0.0001)
(Table 1). In terms of subtypes of adenocarcinoma, high
expression of Bax showed a trend of correlation with bronch-
ioloalveloar carcinoma
(P ¼ 0.094) (Table 2).
ASSOCIATION OF EXPRESSION OF APOPTOSIS-RELATED PROTEINS
WITH PATIENT OUTCOME
The median follow-up duration of surviving patients was 79
months (range: 35–149 months), and one patient with recur-
rence was lost during follow-up because the patient immi-
grated to another country. At the time of analysis, 132 of 205
patients (64%) had died, while 14 patients with either recur-
rence (11 patients) or second primary cancer (three patients)
were alive. Seven patients who died of post-operative compli-
cation were excluded from further survival analysis. Five-year
Table 3. Disease-free and overall survival of the patients according to
various characteristics
a
Characteristics Number
of
patients
5-year
disease-free
survival
(%)
P value
b 5-year
overall
survival
(%)
P value
b
Gender
Female 45 42 0.623 55 0.327
Male 153 36 44
Age
63
c 111 38 0.875 47 0.648
.63 87 36 46
History of smoking
Yes 158 34 0.230 43 0.080
No 40 50 59
Operation
Lobectomy
d 138 37 0.419 49 0.063
Pneumonectomy 60 37 42
Histologic type
Squamous 90 40 0.687 46 0.746
Non-squamous 108 35 46
Tumor size (cm)
3.9
e 103 44 0.019 52 0.026
.3.9 95 29 41
Stage
f
I9 5 5 1 ,0.0001 59 ,0.0001
II 45 33 44
IIIA 44 20 29
IIIB 14 7 21
Resection margin
Negative 181 38 0.155 49 0.037
Positive 17 24 24
Expression of Bax
Low 151 35 0.381
g 45 0.247
h
High 47 45 53
Expression of p53
Low 121 38 0.579 48 0.566
High 77 36 44
Expression of galectin-3
Low 96 34 0.237 42 0.157
High 102 40 50
aExcluding seven patients who died of post-operative complication.
bLog-rank test.
cMedian age.
dIncluding wedge resection.
eMedian longest
diameter of primary tumor.
fPost-operative pathologic staging.
gP ¼ 0.103
according to the Wilcoxon test.
hP ¼ 0.057 according to the Wilcoxon test.
Figure 3. Disease-free survival (A) and overall survival (B) of resected
non-small cell lung cancer patients according to the expression of Bax (P
value was obtained using the Wilcoxon test).
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(Fig. 2). High expressions of p53 and galectin-3 were not
associated with poor DFS or OS (Table 3). Moreover, there
was no signiﬁcant correlation between low expression of Bax
and outcome of patients (Fig. 3 and Table 3). However, in
patients with non-squamous histology (108 patients), low
expression of Bax was a signiﬁcant independent predictor of
poor DFS (P ¼ 0.017) and OS (P ¼ 0.037) in multivariate
analysis (Fig. 4 and Table 4). In addition, in patients with
Stage II or III, low expression of Bax signiﬁcantly correlated
with poor DFS (P ¼ 0.004) (Table 5). It was also the most
signiﬁcant independent prognostic factor second only to a
large primary tumor size in Stage II or III patients with non-
squamous histology (P ¼ 0.001 for DFS, P ¼ 0.013 for OS)
in multivariate analysis as well as in univariate analysis
(Fig. 5 and Table 6).
DISCUSSION
We evaluated the expression of p53, Bax and galectin-3 under
the assumption that abnormalities in these apoptosis-related
proteins may be associated with poor outcome in patients
with NSCLC treated with surgical resection either with or
without adjuvant treatment.
The most frequently investigated apoptosis-related protein
in NSCLC is p53 (11,12,17–22). Although a meta-analysis
demonstrated the association of abnormal p53 status with
poor prognosis of resected NSCLC, the prognostic signiﬁ-
cance of p53 still remains controversial (11,12,17–22).
Among the reports regarding the role of galectin-3 in
NSCLC, one study with only Stage II patients showed the
association of high expression of galectin-3 with poor
outcome (23–25). The results of the present study showed
that high expression of galectin-3 was frequently found in
adenocarcinoma, which is consistent with results reported in
a previous study (25). In addition, high expressions of p53
and galectin-3 were not associated with poor outcome in
patients with resected NSCLC.
The most important ﬁnding of the current study was the
prognostic signiﬁcance of the low expression of Bax in
patients with resected NSCLC, having non-squamous his-
tology or locally advanced disease (Stages II and III),
although it did not predict poor outcome in the entire group
of patients. In the present study, the frequency of low
expression of Bax was very high (94%) in squamous cell
carcinoma. Previous studies also revealed the association of
low expression of Bax with squamous cell carcinoma in
NSCLC (19,26). Therefore, Bax seems to be of little value
as a prognostic indicator in NSCLC patients with squamous
Figure 4. Disease-free survival (A) and overall survival (B) of non-small
cell lung cancer patients with non-squamous histology according to the
expression of Bax (P value was obtained using the Wilcoxon test).
Table 4. Multivariate analysis of disease-free survival and overall survival
in non-squamous histology (n ¼ 108)
a
Prognostic factors Disease-free survival Overall survival
HR 95% CI P value
b HR 95% CI P
value
b
Operation
Lobectomy
c 1.00 1.00
Pneumonectomy 1.41 0.77–2.62 0.269 2.63 1.45–4.79 0.002
Tumor size (cm)
3.9
d 1.00 1.00
.3.9 2.14 1.33–3.45 0.002 1.53 0.90–2.61 0.118
Stage
e
I 1.00 1.00
II 2.65 1.42–4.96 0.002 1.93 0.97–3.85 0.062
IIIA 3.76 2.09–6.77 ,0.0001 2.58 1.40–4.76 0.002
IIIB 5.23 2.08–13.11 ,0.0001 3.52 1.44–8.62 0.006
Expression of Bax
High 1.00 1.00
Low 1.87 1.12–3.14 0.017 1.79 1.04–3.08 0.037
HR, hazard ratio; CI, conﬁdence interval.
aExcluding one patient who died
of post-operative complication.
bCox proportional-hazards regression model.
cIncluding wedge resection.
dMedian longest diameter of primary tumor.
ePost-operative pathologic staging.
666 Low expression of Bax in non-small cell lung cancercell histology. On the other hand, in adenocarcinoma, the
high expression of Bax demonstrated a trend of correlation
with the bronchioloalveolar subtype, which has relatively
higher prevalence in non-smokers and females (27). The
mechanism of extremely high frequency of low expression
of Bax in squamous cell carcinoma remains to be deter-
mined. Considering that almost all squamous cell carcinoma
patients had a history of smoking and there was a strong cor-
relation between smoking history and low expression of Bax
even in adenocarcinoma in the present study (P ¼ 0.014,
data not shown), there is a possibility that smoking might
cause the change in the expression of Bax. However, further
study is essential to prove this speculation. Recently, Tanaka
et al. (28) reported relevant results, which showed that Bax
inhibitor-1 gene expression in adenocarcinoma was higher in
patients with a bronchioloalveolar component and low
smoking index. Since high expression of Bax in adenocarci-
noma demonstrated similar signiﬁcant association with
bronchioloalvelolar subtype and no history of smoking in the
present study, further investigation of the relationship
between Bax and the Bax inhibitor-1 may provide valuable
information for better understanding of the role of Bax in
NSCLC.
To our knowledge, this study is the largest research
project that has investigated the role of Bax in NSCLC.
Unlike for p53 or Bcl-2, there are fewer studies that discuss
the prognostic signiﬁcance of Bax in NSCLC (11,12,19–
22,29–31). In addition, only one study that investigated 61
patients in a predominantly advanced stage (Stage IV, 54%)
demonstrated the correlation between a low expression of
Bax and poor outcome (29).
The poor outcome of patients with low expression of Bax
may be attributed to the intrinsic aggressiveness of the tumor
(11,32). The prognostic value of low expression of Bax was
more signiﬁcant in patients with non-squamous histology,
which had relatively lower proportion of current or previous
smokers compared with squamous cell carcinoma in the
present study. In addition, there was a very strong association
between smoking history and low expression of Bax in
Figure 5. Disease-free survival (A) and overall survival (B) of non-small
cell lung cancer patients in Stage II or III with non-squamous histology
according to the expression of Bax (P value was obtained using the
Wilcoxon test).
Table 5. Multivariate analysis of disease-free survival and overall survival
in Stages II and III (n ¼ 103)
a
Prognostic
factors
Disease-free survival Overall survival
HR 95% CI P value
b HR 95% CI P
value
b
Age
62
c 1.00 1.00
.62 1.40 0.84–2.34 0.202 2.06 1.21–3.53 0.008
Histologic type
Squamous 1.00 1.00
Non-squamous 2.84 1.65–4.89 ,0.0001 1.75 0.99–3.07 0.052
Tumor size (cm)
3.9
d 1.00 1.00
.3.9 2.00 1.26–3.20 0.004 1.94 1.18–3.19 0.009
Stage
e
II 1.00 1.00
IIIA 1.51 0.91–2.49 0.110 1.66 0.96–2.86 0.069
IIIB 1.83 0.93–3.57 0.079 2.29 1.15–4.56 0.019
Resection margin
Negative 1.00 1.00
Positive 2.07 1.04–4.13 0.039 2.21 1.10–4.44 0.026
Chemotherapy
Yes 1.00 1.00
No 1.55 0.98–2.45 0.061 1.47 0.89–2.45 0.136
Expression of Bax
High 1.00 1.00
Low 2.51 1.35–4.66 0.004 1.77 0.92–3.40 0.086
aExcluding ﬁve patients who died of post-operative complication.
bCox
proportional-hazards regression model.
cMedian age.
dMedian longest
diameter of primary tumor.
ePost-operative pathologic staging.
Jpn J Clin Oncol 2008;38(10) 667patients with non-squamous histology (P , 0.0001, data not
shown). These ﬁndings suggest the possibility that more
extensive genetic damage such as low expression of Bax
caused by smoking may result in intrinsic aggressiveness of
the tumor, leading to poor outcome. On the other hand, we
may suppose that resistance to adjuvant chemotherapy or
radiotherapy in tumors with low expression of Bax may be
the cause of poor prognosis, based on the results of the
present study, which demonstrated that the low expression of
Bax predicted poor DFS in Stages II or III when adjuvant
treatments were commonly given (80% of patients)
(8,11–13).
The present study has several potential limitations. First,
this is a retrospective analysis from a single institution with
patients’ cohort within a relatively long period of time.
Second, adjuvant chemotherapy was individualized accord-
ing to the discretion of the treating oncologists, which
resulted in rather heterogeneous chemotherapy regimens,
although cisplatin was included in almost all. Third, the low
expression of Bax did not demonstrate prognostic signiﬁ-
cance in the entire study population.
The association of low expression of Bax with poor DFS
in Stages II or III has a clinical relevance, because adjuvant
chemotherapy has recently been established as a standard of
care for resected Stage II or III NSCLC, and the majority of
patients in these stages in the current study received adjuvant
chemotherapy either with or without radiotherapy (62%)
(2,4–7). In Stage II or III patients with non-squamous
histology, the 5-year OS of patients with low expression of
Bax was signiﬁcantly lower compared with that of high
expression (22 versus 43%, P ¼ 0.012, Wilcoxon test), while
low expression of Bax was one of the signiﬁcant
independent predictors of poor prognosis in multivariate
analysis. Therefore, the present study suggests that locally
advanced (Stage II or III) non-squamous NSCLC patients
with low expression of Bax may require more effective
adjuvant treatment or an intensiﬁed follow-up.
In conclusion, low expression of Bax was signiﬁcantly
associated with the poor outcome in patients with non-
squamous NSCLC. If the prognostic signiﬁcance of low
expression of Bax is validated by further prospective studies
with larger numbers of patients, a relatively simple immunohis-
tochemical staining of surgical specimens for the Bax protein
may provide valuable information to the oncologist for
selecting effective adjuvant treatments or follow-up strategies.
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